| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO, Covance Drug Development
1 company
Kirchgraber Paul R is a CEO, Covance Drug Development at LABCORP HOLDINGS INC.. Recent SEC Form 4 filings include 0 buys and 4 sells.
Estimated insider holdings value: $3.3M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 19, 2023 | LH Labcorp Holdings Inc. | CEO, Covance Drug Development | Sale+OE | 4,300 | $216.91 | $932,706.98 | -24.9% | +14.3% | +13.1% | |
| Feb 21, 2023 | LH Labcorp Holdings Inc. | CEO, Covance Drug Development | Sale+OE | 8,000 | $250.58 | $2,004,675.20 | -46.9% | -11.1% | +3.2% | |
| May 6, 2021 | LH Labcorp Holdings Inc. | CEO, Covance Drug Development | Sell | 2,500 | $276.55 | $691,375.00 | -24.2% | +7.9% | -9.6% | |
| Nov 4, 2020 | LH Labcorp Holdings Inc. | CEO, Covance Drug Development | Sell | 1,500 | $214.14 | $321,203.55 | -16.3% | - | - |